All In Biotech

Drug Trial Radar · NCT07192952

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Dec 30, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure with left ventricular systolic dysfunction (LVSD) is a condition where the left side of the heart is weak and struggles to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and poor growth. The study treatment, finerenone (also called BAY94-8862), is under development to treat newborns, children, and young adults with heart failure and LVSD. It works by blocking a protein that contributes to inflammation, scarring, and thickening in the heart and blood vessels, which may help the heart pump more blood effectively. The main purpose of this study is to learn about how safe finerenone is and how well it works in the long-term treatment of heart failure and LVSD. To understand how safe the treatment is, the study team will gather information on the number of patients who experience medical problems after taking finerenone, also known as "treatment emergent adverse events" (TEAEs). Additionally, they will collect blood samples to measure levels of an electrolyte called potassium and monitor blood pressure. They will also assess kidneys function using the estimated glomerular filtration rate (eGFR). In this study, which is an extension of the earlier done FIORE study, finerenone will also be studied in newly enrolled newborns under 6 months with heart failure and LVSD and children and young adults from the FIORE study. The participants will be aged from newborns up to 18 years. All the participants will continue to receive their standard treatment as routine care for heart failure, along with finerenone during the study. The participants will be in the study for around 10 to 11 months, depending on whether they rolled-over from the FIORE study or are newly enrolled newborns and infants \<6 months of age. They will take study treatment for up to 9 months. During this period, at least 6 visits are planned for participants. During these visits, the study team will: * have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured * have blood samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography * answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answer * for newborns and infants, evaluate the acceptability of the study drug formulation through parents or guardians' feedback. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health a month after the participants take their last treatment.

Conditions

  • Left Ventricular Systolic Dysfunction
  • Heart Failure (Pediatric)

Interventions

  • Finerenone (Kerendia, BAY94-8862)Drug

    Finerenone in different doses, treatment duration will be 270±7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: From the start of study intervention to last study intervention (up to 277 days) + 3 days
  2. Change in serum potassium levelsTime frame: From baseline to Day 270±7
  3. Change in systolic blood pressure (SBP)Time frame: From baseline to Day 270±7
  4. Change in estimated glomerular filtration rate (eGFR)Time frame: From baseline to Day 270±7

Locations

132 sites in 23 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado - Anschutz Medical Campus - Cardiology

    Aurora, Colorado · Not yet recruiting

  • Nemours Children's Hospital - Delaware - Cardiology

    Wilmington, Delaware · Not yet recruiting

  • UF Health Shands Hospital - Pediatric Cardiology

    Gainesville, Florida · Not yet recruiting

  • Joe Dimaggio Children's Hospital - Cardiology

    Hollywood, Florida · Not yet recruiting

  • Emory University Hospital - Children's Healthcare of Atlanta Cardiology - Atlanta

    Atlanta, Georgia · Not yet recruiting

  • Riley Hospital For Children - Cardiology

    Indianapolis, Indiana · Not yet recruiting

  • Boston Children's Hospital - Main Campus - Cardiology

    Boston, Massachusetts · Not yet recruiting

  • C.S. Mott Children's Hospital - Cardiology

    Ann Arbor, Michigan · Not yet recruiting

  • Children's Mercy Hospital Kansas City - Cardiology

    Kansas City, Missouri · Not yet recruiting

  • Washington University - St. Louis Children's Hospital - Cardiology

    St Louis, Missouri · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai - Pediatric Cardiology

    New York, New York · Not yet recruiting

  • Columbia University Irving Medical Center - Pediatric Cardiology

    New York, New York · Not yet recruiting

  • The Children's Hospital at Montefiore - Cardiology

    The Bronx, New York · Not yet recruiting

  • Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

    Cincinnati, Ohio · Not yet recruiting

  • Cleveland Clinic Children's

    Cleveland, Ohio · Not yet recruiting

  • Nationwide Children's Hospital - Cardiology

    Columbus, Ohio · Not yet recruiting

  • Children's Hospital of Philadelphia - Cardiology

    Philadelphia, Pennsylvania · Not yet recruiting

  • UPMC Children's Hospital of Pittsburgh - Cardiology

    Pittsburgh, Pennsylvania · Not yet recruiting

  • MUSC Shawn Jenkins Children's Hospital - Cardiology

    North Charleston, South Carolina · Not yet recruiting

  • Children's Medical Center Dallas - Cardiology

    Dallas, Texas · Not yet recruiting

  • Texas Children's Hospital - Cardiology

    Houston, Texas · Not yet recruiting

  • Eccles Primary Children's Outpatient Services - Cardiology

    Salt Lake City, Utah · Not yet recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Not yet recruiting

  • Hospital de Pediatría Juan P. Garrahan

    Buenos Aires, Argentina · Not yet recruiting

  • Hospital General de Ninos Pedro de Elizalde | Nephrology Department

    Buenos Aires, Argentina · Not yet recruiting

  • Consultorios Médicos Dr. Doreski

    Buenos Aires, Argentina · Not yet recruiting

  • Sanatorio de la Cañada

    Córdoba, Argentina · Not yet recruiting

  • Centro Cardiovascular Salta (Torzav SRL)

    Salta, Argentina · Not yet recruiting

  • Hospital de Niños Sor María Ludovica

    La Plata, Buenos Aires, Argentina · Not yet recruiting

  • Instituto De Investigaciones Clinicas Zarate | Zarate, Argentina

    Zárate, Buenos Aires, Argentina · Not yet recruiting

  • Hospital General de Ninos Ricardo Gutierrez | Cardiology Department

    Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina · Not yet recruiting

  • Consultorios Integrados Rosario | Instituto Medico de la Fundacion de Estudios Clinicos

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • Medizinische Universität Wien - Klinik für Kinder- und Jugendheilkunde, Abteilung für Pädiatrische Kardiologie

    Vienna, State of Vienna, Austria · Not yet recruiting

  • Kepler Universitätsklinikum GmbH - Klinik für Kinderkardiologie

    Linz, Upper Austria, Austria · Not yet recruiting

  • CHC MontLegia - Pediatric Cardiology

    Liège, Belgium · Not yet recruiting

  • UZ Antwerpen - Pediatric Cardiology

    Edegem, Antwerp, Belgium · Not yet recruiting

  • Cliniques Universitaires St-Luc (UCL) - Pediatric Cardiology

    Brussels, Brussels Capital, Belgium · Recruiting

  • UZ Gent - Pediatric Cardiology

    Ghent, East Flanders, Belgium · Not yet recruiting

  • UZ Leuven - Pediatric Cardiology

    Leuven, Flemish Brabant, Belgium · Not yet recruiting

  • Hospital Infantil Sabará - Instituto PENSI - Pesquisa e Ensino em Saúde Infantil

    São Paulo, Brazil · Not yet recruiting

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.